AlphAIAlphAI — Financial news for AI agents
fool.comAUG 203 min read$OPRX

OptimizeRx (OPRX) Q2 2026 Earnings Call Transcript

OptimizeRx (OPRX) reported Q2 2026 revenue of $20.5M, down 30% YoY due to lower-margin services and customer inactivity. Adjusted EBITDA was $4.9M. Full-year guidance was reaffirmed: $95M-$100M revenue and $21M-$25M adjusted EBITDA. AI software revenue grew 25% YoY. Cash and cash equivalents were $24.1M, with debt reduced to $19.7M. Management highlighted strategic shifts and leadership transitions. (350 characters)

Original reporting
fool.com
Published Aug 20, 2026, 12:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 1:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
OptimizeRx (OPRX) Q2 2026 Earnings Call Transcript — source image
Source · fool.com
Decision brief

The 30-second read

$OPRXBullishMed
01

Why it matters

Earnings beat and reaffirmed guidance suggest the transition is progressing, but revenue contraction and customer concentration remain risks.

02

Market read

Micro‑cap healthcare‑tech stock with fresh earnings data; relevant for short‑term traders and sector specialists.

03

What to watch

Debt repayment schedule and upcoming CFO transition may affect near‑term liquidity.

Relevance 6/10Novelty 8/10Timing: post‑earnings Q2 2026 release

Background

OptimizeRx is transitioning from low‑margin managed services to higher‑margin AI software for pharma marketers.

Company-level read

Ticker impact

$OPRXBullishHigh confidence
Context

Q2 2026 earnings release with revenue $20.5M, adjusted EBITDA $4.9M, and reaffirmed full-year guidance.

Expected impact

Potential short-term upside as investors digest beat and guidance.

Evidence & confidence

First report of earnings numbers and guidance for a micro‑cap; beat and reaffirmation are actionable.

Market effects

Sector

Highlights AI‑enabled software growth in healthcare advertising sector.

Regional

US healthcare tech niche may see modest re‑rating.

Global

Limited to investors tracking niche pharma‑tech firms.

Counterpoint

What could challenge this read

Revenue decline and high customer concentration could pressure the stock despite earnings beat.

Key entities

  • Executive
    Stephen L. Silvestro

    CEO of OptimizeRx

  • Executive
    Edward Stelmakh

    Chief Financial Strategy Officer, soon to be CFO successor

Read at source← All news

Related articles

AUG 12
$OPRXMed

OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance

OptimizeRx Corp (OPRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance - Q2 revenue totals $20.5 million - Q2 net loss and adjusted EBITDA of $(0.7) million and $4.9 million, respectively - Reaffirms fiscal year 2026 revenue guidance of $95 - $100 million

SEC EDGAR 8-K4 min
OCT 28
$VRTHighAI 9/10

Vertiv stock surges as orders double amid AI build-out

Vertiv (VRT) stock rose 15% premarket after reporting strong Q3 results and raising its full-year outlook. Orders doubled year-over-year due to AI-driven data center demand. The company expects 2026 sales of $14.45B-$14.85B and EPS of $7.10-$7.20, exceeding analyst estimates. Key customers include Google (GOOG), Microsoft (MSFT), Nvidia (NVDA), and Amazon (AMZN).

finance.yahoo.com5 min
OCT 28
$CLHHighAI 9/10

Clean Harbors Announces Third-Quarter 2026 Financial Results

CLEAN HARBORS INC (CLH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Press Release Clean Harbors Announces Third-Quarter 2026 Financial Results • Delivers 21% Growth in Revenues to a Record $1.87 Billion, Driven by Both Operating Segments • Generates 75% Increase in Q3 Net Income to $208.1 Million, or EPS of $3.93 • Achieves 42% Growt

SEC EDGAR 8-K6 min